CDK9 inhibitor - Pipeline Insight, 2022
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Cyclin-Dependent Kinase 9 (CDK9) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cyclin-Dependent Kinase 9 (CDK9) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor: Overview
CDK9 is not a typical Cdc2-like kinase. It does not act in cell-cycle regulation processes; rather, it acts in differentiation processes. It is the catalytic subunit of P-TEFb that, in association with Cyclin T, has the ability to phosphorilate the CTD substrate of RNA polymerase II and reach the RNA transcription elongation. There are 2 isoforms of the CDK9 protein: the major 42 kDa CDK9 isoform, and the minor 55 kDa isoform.
Function –CDK9 is not a typical Cdc2-like kinase. It does not act in cell-cycle regulation processes; rather, it acts in differentiation processes. It is the catalytic subunit of P-TEFb that, in association with Cyclin T, has the ability to phosphorilate the CTD substrate of RNA polymerase II and reach the RNA transcription elongation.Although there are other cyclin-dependent kinases that are capable of phosphorilating the CTD, the only one that activates gene expression in a catalyst manner is CDK9.
Cyclin-Dependent Kinase 9 (CDK9) Inhibitors- CDK9 is one of the major Pol II-directed kinases of P-TEFb. A number of small-molecule inhibitors of CDK9 kinase activity directed to the ATP-binding pocket have been developed and tested. A number of natural compounds have been identified as non-selective inhibitors of CDKs. The bis-indoles indirubins were the first human-used compounds to be identified as CDK inhibitors. CDK9 Blockade is A Potential Treatment For Pediatric Soft Tissue Sarcomas.
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Emerging Drugs Chapters
This segment of the Cyclin-Dependent Kinase 9 (CDK9) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Emerging Drugs
Further product details are provided in the report……..
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cyclin-Dependent Kinase 9 (CDK9) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Cyclin-Dependent Kinase 9 (CDK9) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cyclin-Dependent Kinase 9 (CDK9) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor: Overview
CDK9 is not a typical Cdc2-like kinase. It does not act in cell-cycle regulation processes; rather, it acts in differentiation processes. It is the catalytic subunit of P-TEFb that, in association with Cyclin T, has the ability to phosphorilate the CTD substrate of RNA polymerase II and reach the RNA transcription elongation. There are 2 isoforms of the CDK9 protein: the major 42 kDa CDK9 isoform, and the minor 55 kDa isoform.
Function –CDK9 is not a typical Cdc2-like kinase. It does not act in cell-cycle regulation processes; rather, it acts in differentiation processes. It is the catalytic subunit of P-TEFb that, in association with Cyclin T, has the ability to phosphorilate the CTD substrate of RNA polymerase II and reach the RNA transcription elongation.Although there are other cyclin-dependent kinases that are capable of phosphorilating the CTD, the only one that activates gene expression in a catalyst manner is CDK9.
Cyclin-Dependent Kinase 9 (CDK9) Inhibitors- CDK9 is one of the major Pol II-directed kinases of P-TEFb. A number of small-molecule inhibitors of CDK9 kinase activity directed to the ATP-binding pocket have been developed and tested. A number of natural compounds have been identified as non-selective inhibitors of CDKs. The bis-indoles indirubins were the first human-used compounds to be identified as CDK inhibitors. CDK9 Blockade is A Potential Treatment For Pediatric Soft Tissue Sarcomas.
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Emerging Drugs Chapters
This segment of the Cyclin-Dependent Kinase 9 (CDK9) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Emerging Drugs
- Dinaciclib: Merck & Co
- KB-0742: Kronos Bio
- Alvocidib: Sumitomo Dainippon Pharma Oncology
Further product details are provided in the report……..
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Cyclin-Dependent Kinase 9 (CDK9) Inhibitor
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cyclin-Dependent Kinase 9 (CDK9) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cyclin-Dependent Kinase 9 (CDK9) Inhibitor R&D. The therapies under development are focused on novel approaches for Cyclin-Dependent Kinase 9 (CDK9) Inhibitor.
- Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drugs?
- How many Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Cyclin-Dependent Kinase 9 (CDK9) Inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cyclin-Dependent Kinase 9 (CDK9) Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cyclin-Dependent Kinase 9 (CDK9) Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
- Merck & Co
- Kronos Bio
- Sumitomo Dainippon Pharma Oncology
- AstraZeneca
- Kino Pharma
- Cyclacel Pharmaceuticals
- Bayer
- MEI Pharma
- Syros Pharmaceuticals
- BioTheryX
- Le Sun Pharmaceuticals
- NeoSome Life Sciences
- Adastra Pharmaceuticals/S*Bio
- Virostatics
- GenFleet Therapeutics
- ASINEX
- Dinaciclib
- KB-0742
- Alvocidib
- AZD 4573
- TP 1287
- FIT 039
- BAY 1251152
- Seliciclib
- Fadraciclib
- Voruciclib
- SY 5609
- BTX A51
- Research programme: cancer therapeutics
- NEOS 518
- Zotiraciclib
- Research programme: anticancer therapeutics
- Research programme: cyclin-dependant kinases
- GFH 009
Introduction
Executive Summary
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Dinaciclib: Merck & Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Alvocidib : Sumitomo Dainippon Pharma Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
KB-0742: Kronos Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
MRTX-1133: Mirati Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Key Companies
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Key Products
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor- Unmet Needs
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor- Market Drivers and Barriers
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor- Future Perspectives and Conclusion
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Analyst Views
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Key Companies
Appendix
Executive Summary
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Dinaciclib: Merck & Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Alvocidib : Sumitomo Dainippon Pharma Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
KB-0742: Kronos Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
MRTX-1133: Mirati Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Key Companies
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Key Products
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor- Unmet Needs
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor- Market Drivers and Barriers
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor- Future Perspectives and Conclusion
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Analyst Views
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Cyclin-Dependent Kinase 9 (CDK9) Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Cyclin-Dependent Kinase 9 (CDK9) Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Cyclin-Dependent Kinase 9 (CDK9) Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Cyclin-Dependent Kinase 9 (CDK9) Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
